大唐药业
(836433)
| 流通市值：8.14亿 | | | 总市值：12.45亿 |
| 流通股本：1.69亿 | | | 总股本：2.59亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 38,103,723.62 | 188,252,662.38 | 148,221,522.62 | 123,160,631.48 |
| 营业收入 | 38,103,723.62 | 188,252,662.38 | 148,221,522.62 | 123,160,631.48 |
| 二、营业总成本 | 36,896,109.7 | 183,583,530.59 | 138,869,134.76 | 99,780,975.56 |
| 营业成本 | 8,301,161.79 | 53,811,462.88 | 43,089,716.64 | 36,121,048.15 |
| 税金及附加 | 63,838.35 | 3,547,146.01 | 2,159,269.22 | 2,132,840.28 |
| 销售费用 | 20,717,841.19 | 92,488,721.6 | 68,287,664.54 | 45,927,181.69 |
| 管理费用 | 7,604,805.52 | 25,636,032.56 | 20,630,152.05 | 13,105,959.3 |
| 研发费用 | 1,238,549.82 | 7,072,545.71 | 5,213,689.86 | 3,228,955.63 |
| 财务费用 | -1,030,086.97 | 1,027,621.83 | -511,357.55 | -735,009.49 |
| 其中:利息费用 | -375,289.71 | 2,306,667.89 | 1,614,415.66 | 626,437.99 |
| 其中:利息收入 | 655,366.51 | 1,300,571.35 | 2,139,858.69 | 1,366,201.82 |
| 加:公允价值变动收益 | 102,578.82 | 663,716.94 | 281,894.79 | 449,599.4 |
| 加:投资收益 | 46,956.91 | 2,428,706.11 | 1,100,620.11 | 618,741.3 |
| 资产减值损失(新) | 167,601.38 | -1,501,307.84 | -6,068.43 | 39,088.25 |
| 信用减值损失(新) | -298,936.7 | -535,136.92 | 115,273.28 | 57,276.75 |
| 其他收益 | 351,587.59 | 3,606,148.86 | 1,868,409.51 | 1,214,143.32 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,577,401.92 | 9,331,258.94 | 12,712,517.12 | 25,758,504.94 |
| 加:营业外收入 | 94,501 | 1,816,457.3 | 1,643,944.6 | 39,044.6 |
| 减:营业外支出 | - | 511,295 | 61,295 | - |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,671,902.92 | 10,636,421.24 | 14,295,166.72 | 25,797,549.54 |
| 减:所得税费用 | 439,229.16 | 2,708,784.79 | 3,843,301.13 | 3,989,793.42 |
| 六、净利润 | 1,232,673.76 | 7,927,636.45 | 10,451,865.59 | 21,807,756.12 |
| 持续经营净利润 | 1,232,673.76 | 7,927,636.45 | 10,451,865.59 | 21,807,756.12 |
| 归属于母公司股东的净利润 | 1,232,673.76 | 7,927,636.45 | 10,451,865.59 | 21,807,756.12 |
| (一)基本每股收益 | 0.01 | 0.03 | 0.04 | 0.09 |
| (二)稀释每股收益 | 0.01 | 0.03 | 0.04 | 0.09 |
| 九、综合收益总额 | 1,232,673.76 | 7,927,636.45 | 10,451,865.59 | 21,807,756.12 |
| 归属于母公司股东的综合收益总额 | 1,232,673.76 | 7,927,636.45 | 10,451,865.59 | 21,807,756.12 |
| 公告日期 | 2024-04-22 | 2024-03-20 | 2023-10-27 | 2023-08-17 |
| 审计意见(境内) | | 标准无保留意见 | | |